➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Mallinckrodt
Harvard Business School
Baxter
Moodys

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Rucaparib camsylate - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic sources for rucaparib camsylate and what is the scope of patent protection?

Rucaparib camsylate is the generic ingredient in one branded drug marketed by Clovis Oncology Inc and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Rucaparib camsylate has two hundred and seventy-six patent family members in fifty-three countries.

One supplier is listed for this compound.

Summary for rucaparib camsylate
International Patents:276
US Patents:12
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 21
Clinical Trials: 6
Patent Applications: 1
DailyMed Link:rucaparib camsylate at DailyMed
Recent Clinical Trials for rucaparib camsylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 3
Alliance for Clinical Trials in OncologyPhase 3
Clovis Oncology, Inc.Phase 2

See all rucaparib camsylate clinical trials

Pharmacology for rucaparib camsylate

US Patents and Regulatory Information for rucaparib camsylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-002 Dec 19, 2016 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-003 May 1, 2017 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for rucaparib camsylate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2534153 2018C/044 Belgium ⤷  Free Forever Trial PRODUCT NAME: RUCAPARIB-CAMSYLAAT; AUTHORISATION NUMBER AND DATE: EU/1/17/1250 20180529
2534153 2018/043 Ireland ⤷  Free Forever Trial PRODUCT NAME: RUCAPARIB CAMSYLATE; REGISTRATION NO/DATE: EU/1/17/1250 20180524
2534153 PA2018517,C2534153 Lithuania ⤷  Free Forever Trial PRODUCT NAME: RUKAPARIBO KAMSILATAS; REGISTRATION NO/DATE: EU/1/17/1250 20180524
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Mallinckrodt
Harvard Business School
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.